Product Details

Ondansetron ODT (Tablet)

Ondansetron Hydrochloride
4 mg



DIN/PIN/NPN

02524279

Manufacturer

Sanis Health Inc.

Formulary Listing Date

2023-11-30  

Unit Price

3.2720

Amount MOH Pays

2.5450

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

A04AA01

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02239372 Zofran ODT (Tablet) 15.6550 2.5450
02444674 VPI-Ondansetron ODT (Tablet) 3.2720 2.5450
02389983 Ondissolve ODF (Film) 3.2720 2.5450
02481723 Ondansetron ODT (Tablet) 3.2720 2.5450
02487330 Mint-Ondansetron ODT (Tablet) 3.2720 2.5450
02511282 Auro-Ondansetron ODT (Tablet) 3.2720 2.5450
02514966 Mar-Ondansetron ODT Tablet 3.2720 2.5450
02519232 Ondansetron ODT (Tablet) 3.2720 2.5450
02519445 PMS-Ondansetron ODT Tablet 3.2720 2.5450
02524279 Ondansetron ODT (Tablet) 3.2720 2.5450
02535319 Accel-Ondansetron ODT (Tablet) 2.5450 2.5450
02541351 Jamp Ondansetron ODF 3.2720 2.5450
 

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
Note: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven
215 1 year

For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy

216 1 year

For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics

217 1 year

For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics

218 1 year

For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.

454 1 year

For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens

 

EAP Criteria

NO

Product Monograph

View Monograph